FDA Clears AI-Powered CT Assessment Tool for Lung Fibrosis
For patients with suspected interstitial lung disease, the digital biomarker solution Fibresolve offers machine learning capability of diagnosing idiopathic pulmonary fibrosis (IPF) based on assessment of lung computed tomography (CT) scans.
While the diagnosis of lung fibrosis currently may not occur up to two and a half years after initial symptoms, the Food and Drug Administration (FDA) has granted De Novo clearance to Fibresolve, an emerging artificial intelligence (AI)-enabled software that may facilitate earlier diagnosis and timely treatment.
Utilizing machine learning pattern recognition to assess lung computed tomography (CT) scans, Fibresolve may facilitate the diagnosis of lung fibrosis and possibly idiopathic pulmonary fibrosis (IPF), according to Imvaria, the developer of Fibresolve. The company added that Fibresolve can provide subtype classification in cases involving suspected interstitial lung disease (ILD).
The capability of Fibresolve to provide adjunctive qualitative classification of CT imaging findings previously garnered Breakthrough Device Designation from the FDA. Imvaria noted the software also has established CPT billing codes.
“Fibresolve serves as an adjunct to clinicians in assessing patients with suspected lung fibrosis to provide a diagnostic subtype classification, potentially facilitating proper treatments at an earlier stage of the disease process,” said Joshua Reicher, M.D., co-founder and CEO of Imvaria. “The FDA’s authorization of Fibresolve marks a significant milestone, not only for lung fibrosis patients, but also for the advancement of AI-based healthcare technologies.”
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
